Blockage of PD-1 and/or CTLA-4 can lead to the stimulation and augmentation of anti-tumor effects via the activation of tumor-specific cytotoxic T-cells and inhibition of regulatory T cells (Tregs) (2). Here, RPL17 is linked to neoplasm.